5

PHENYLTHIOMETHYL-6-HYDROXY-2.3-DIHY-DROBENZO-PYRAN AND ANALOGS THEREOF **USEFUL AS ANTI-INFLAMMATORY AGENTS**

BACKGROUND OF THE INVENTION

The present invention relates to novel substituted 6-hydroxy-2,3-dihydrobenzopyran and analogs thereof useful as anti-inflammatory agents.

It has been observed that the novel compounds of this 10 invention are active in vitro in both the peritoneal macrophage assay and the polymorphonuclear leukocyte assay for general anti-inflammatory activity. Specifically, they are found to be active in vivo in the mouse ear assay for topical anti-inflammatory agents. Further- 15 more, these compounds tend to be inactivated in vivo after deeper and longer penetration into the body system and are therefore devoid of any significant adverse side effects normally associated with systemic activity.

Recent studies demonstrated that macrophages par- 20 ticipate in the development and progression of chronic inflammatory diseases such as rheumatoid arthritis. During the progression of inflammatory conditions, there is generally an appearance and/or presence of macrophages and lymphocytes, especially macrophages 25 and polymorphonuclear leukocytes. Macrophages are known to secrete various products in response to inflammatory stimuli. For example:

- (1) Neutral proteases—the destructive peptide bond cleaving enzymes which have been shown to be 30 directly involved in rheumatoid cartilage destruction; and
- (2) Prostaglandins (PG) (e.g., E₂ and I₂ by mouse peritoneal macrophages) and other arachidonic acid derivatives derived from both the cyclooxyge- 35 nase and the lipoxygenase pathways.

These arachidonic acid oxygenation products have been identified as the critical mediators of various acute inflammatory conditions.

Accordingly, pharmacological agents which are ca- 40 pable of inhibiting the formation or the release of a mediator and thereby interfere with the function of macrophages or polymorphonuclear leukocytes may also be effective anti-inflammatory agents. For example, nonsteroidal anti-inflammatory drugs such as indometh- 45 acin and clinoril are known cyclooxygenase inhibitors. Through their ability to inhibit the formation of prostaglandins, they have been used for rheumatoid arthritis and osteoarthritis. Other inflammatory diseases such as emphysema, bronchial inflammation, acute respiratory 50 m is an integer ranging from 1 to 4; distress syndrome, spondylitis, lupus, gout, and psoriasis may also be treated with these pharmacological agents.

Regarding the topical mouse ear assay, it has been previously established that classical nonsteroidal antiinflammatory agents such as indomethacin and steroidal 55 anti-inflammatory agents such as dexamethasone are active in this assay.

Another object of this invention is to provide appropriate processes for the preparation of the subject novel compounds.

Still a further object of the present invention is to provide a pharmaceutically acceptable composition containing an effective amount of the active compound for the treatment of various inflammatory conditions.

Finally, it is the ultimate object of this invention to 65 develop a method of treating inflammation via the administration of a therapeutically effective amount of the novel compounds or pharmaceutically acceptable com-

position thereof to a mammalian species in need of such

DETAILED DESCRIPTION OF THE INVENTION

A. Scope of the Invention

This invention relates to novel compounds of formula (I) and (II)

HO
$$(CH_2)_m$$
 or $(R)_m$ (I) A (II)

or a pharmaceutically acceptable salt thereof, wherein

(a) hydroxyloweralkyl especially C_{1-6} hydroxyalkyl such as -CH2OH, -CH2CH2OH or

- (b) lower alkanoyl;
- (c) CN;
- (d) halo;
- (e) mercaptoloweralkyl especially mercapto C₁₋₆ alkyl such as -CH2SR2 where R2 represents H or loweralkyl.
- (f) loweralkylthio especially C₁₋₆alkylthio such as -SCH₃;
- (g) lowerhaloalkyl;
- (h) --COOR2;
- (i) hydroxycarbonylloweralkyl especially hydroxyearbonyl-C₁₋₆ alkyl such as —CH₂COOH;
- (j) loweralkoxycarbonylloweralkyl especially C₁₋₆ alkoxycarbonyl C₁₋₆ alkyl such as -CH₂COO
- (k) haloloweralkanoyl especially halo C₁₋₆ alkanoyl such as trifluoroacetyl;
- (1) loweralkoxy especially C₁₋₆ alkoxy such as methoxy, ethoxy and propoxy, with the proviso that R cannot be loweralkoxy when A is phenyl; or
- (m) loweralkanovloxyloweralkyl such as -CH-2OCOCH3;

- (a) phenyl substituted with $(R^1)_q$ wherein when there are more than one R^1 (i.e., q>1), they can be the same or different from each other and is
 - (1) hydrogen;
 - (2) halo especially fluorb, chloro or bromo;
 - (3) loweralkoxy especially C₁₋₆ alkoxy, e.g., methoxy, ethoxy, isopropoxy, t-butoxy or cyclohexyloxy, or -OCH2O-
 - (4) lower alkylthio especially C₁₋₆ alkylthio, or C₁₋₆ haloalkylthio e.g., methylthio, ethylthio, trifluoromethylthio or cyclohexylthio;
 - (5) lower alkyl sulfinyl especially C₁₋₆ alkyl sulfinyl, e.g., methyl sulfinyl, i-propyl sulfinyl, and cyclopentyl sulfinyl;
 - (6) lower alkyl sulfonyl especially C₁₋₆ alkyl sulfonyl such as methyl sulfonyl, ethyl sulfonyl and n-butyl sulfonyl;